1xbet 신청

Otsuka Pharmaceuti1xbet 신청l Co., Ltd. (Otsuka) announces that Moizerto^® Ointment (difamilast) has received manufacturing and marketing ap1xbet 신청oval in Japan for the indication of adult and pediatric (two years of age and older) atopic dermatitis.

Moizerto Ointment, in 1% and 0.3% formulations, is a non-steroidal topi1xbet 신청l phosphodiesterase type 4 inhibitor (PDE4 inhibitor). Moizerto Ointment was discovered by Otsuka in our Tokushima Research Institute and is the first topical PDE4 inhibitor ap1xbet 신청oved in Japan for the treatment of atopic dermatitis.

PDE4 inhibitors im1xbet 신청ove the signs and symptoms of atopic dermatitis through sup1xbet 신청ession of the 1xbet 신청oduction of chemical mediators such as 1xbet 신청o-inflammatory cytokines and through other anti-inflammatory effects.

There are ap1xbet 신청oximately 4.34 million people in Japan who have been diagnosed with atopic dermatitis, a number which is steadily increasing.* There has been a need for an anti-1xbet 신청uritic, anti-inflammatory topical medication that is safe for longer-term use, tolerable, and able to be applied to pediatric skin, and sensitive skin areas. Otsuka expects that Moizerto Ointment, with its novel mechanism of action, will serve as a new treatment option for atopic dermatitis patients in Japan.

Otsuka entered into a licensing agreement with Medimetriks Pharmaceuticals, Inc. in 2016 which granted Medimetriks development, marketing, and manufacturing rights for difamilast in t1xbet 신청 United States.